The Accelerated mAb development program reduces development timelines for IgG1 and IgG4 monoclonal antibodies to 9 months using an established, phase-appropriate process that is scalable and integrates strategies for risk mitigation. The program is designed to ensure that quality, safety, and regulatory requirements for IND/IMPD filing and early clinical trials are met, and a robust foundation for future commercial-scale production is established. In this webinar, you’ll hear from some of the experts who were instrumental in developing the Accelerated mAb development program and work with our biotech clients on a daily basis to accelerate their timelines toward the production of GMP drug substances.
In this webinar, you will learn about:
Armelle Gilletta de Saint Joseph
Analytical Laboratory Supervisor
Operational QA Expert
Head of Manufacturing Science and Technology, Biologics CDMO
Jean-Baptiste joined MilliporeSigma as a bioproduction process and equipment engineer in 2013. Since he joined the company, he has been responsible for leading the technical transfer of biotech products and the cleaning and process validation (PPQ) for new products as well as supporting the troubleshooting of clinical and commercial manufacturing. His role expanded in 2014 when he became Manufacturing Science and Technology Manager for our Biologics CDMO and took on the responsibility of setting up a Manufacturing Science and Technology team to continue driving these activities.
DSP Development Expert
DSP Innovation Expert
To continue reading please sign in or create an account.Don't Have An Account?